HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for hydrochlorothiazide; propranolol hydrochloride and what is the scope of patent protection?

Hydrochlorothiazide; propranolol hydrochloride is the generic ingredient in seven branded drugs marketed by Wyeth Ayerst, Wyeth Pharms Inc, Duramed Pharms Barr, Actavis Elizabeth, Ani Pharms, Chartwell Rx, Ivax Sub Teva Pharms, Rising, Warner Chilcott, and Watson Labs, and is included in nineteen NDAs. Additional information is available in the individual branded drug profile pages.

Summary for HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

US Patents:	0
Tradenames:	7
Applicants:	10
NDAs:	19
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
DailyMed Link:	HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE at DailyMed

Recent Clinical Trials for HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
US Department of Veterans Affairs
VA Office of Research and Development

See all HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

C03AA	Thiazides, plain
C03A	LOW-CEILING DIURETICS, THIAZIDES
C03	DIURETICS
C	Cardiovascular system

C03AA	Thiazides, plain
C03A	LOW-CEILING DIURETICS, THIAZIDES
C03	DIURETICS
C	Cardiovascular system

C07AA	Beta blocking agents, non-selective
C07A	BETA BLOCKING AGENTS
C07	BETA BLOCKING AGENTS
C	Cardiovascular system

US Patents and Regulatory Information for HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Warner Chilcott	PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; propranolol hydrochloride	TABLET;ORAL	071772-001	Jan 26, 1988		DISCN	No	No
Ivax Sub Teva Pharms	PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; propranolol hydrochloride	TABLET;ORAL	071553-001	Dec 1, 1988		DISCN	No	No
Actavis Elizabeth	PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; propranolol hydrochloride	TABLET;ORAL	070851-001	May 15, 1986		DISCN	No	No
Wyeth Ayerst	INDERIDE LA 120/50	hydrochlorothiazide; propranolol hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	019059-002	Jul 3, 1985		DISCN	No	No
Ani Pharms	PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; propranolol hydrochloride	TABLET;ORAL	072043-001	Mar 14, 1988		DISCN	No	No
Actavis Elizabeth	PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; propranolol hydrochloride	TABLET;ORAL	070852-001	May 15, 1986		DISCN	No	No
Ani Pharms	PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; propranolol hydrochloride	TABLET;ORAL	070705-002	Oct 1, 1986		DISCN	No	No

Expired US Patents for HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Wyeth Ayerst	INDERIDE LA 120/50	hydrochlorothiazide; propranolol hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	019059-002	Jul 3, 1985	4,138,475
Wyeth Ayerst	INDERIDE LA 160/50	hydrochlorothiazide; propranolol hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	019059-003	Jul 3, 1985	4,138,475
Wyeth Ayerst	INDERIDE LA 80/50	hydrochlorothiazide; propranolol hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	019059-001	Jul 3, 1985	4,138,475

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for Hydrochlorothiazide and Propranolol Hydrochloride?

Hydrochlorothiazide and propranolol hydrochloride are longstanding, generic medications with established markets. Their demand profiles depend heavily on regulatory status, patent expirations, and the prevalence of the conditions they treat.

Hydrochlorothiazide (HCTZ)

Market Overview
HCTZ is a diuretic primarily used for hypertension and edema management. It held a dominant position among antihypertensive agents until the mid-2010s, but its market share has declined due to safety concerns associated with long-term use.

Market Drivers

• Persistently high prevalence of hypertension globally, especially in low- and middle-income countries.
• Continued use as a first-line antihypertensive in combination therapies.
• Generics dominate U.S. and European markets, leading to competitive pricing.

Market Constraints

• Rising awareness of potential side effects, such as electrolyte imbalance and increased risk of skin cancer, has prompted clinicians to prefer alternative agents.
• Regulatory advisories and updates shifted prescribing behaviors, with some institutions reducing HCTZ prescriptions in favor of other diuretics or antihypertensives.

Pricing and Revenue Trends

• The drug generates low per-unit revenue due to generic status.
• Global sales are estimated in the hundreds of millions annually, with North America accounting for the majority.
• Market prices trend downward as patents have long expired, with prices in developing regions even lower due to generic competition.

Propranolol Hydrochloride

Market Overview
Propranolol is a beta-blocker indicated for hypertension, arrhythmias, migraines, and certain anxiety disorders. Market adoption has historically been high, but newer agents have begun to supplant it for some indications.

Market Drivers

• Long-standing efficacy and safety profile support sustained demand.
• Widely used off-label for anxiety and performance anxiety, expanding its patient utilization.
• Pending patent expirations have increased generic availability, keeping prices low.

Market Constraints

• Rise of cardioselective beta-blockers (e.g., atenolol, metoprolol) with fewer contraindications limits propranolol’s market share in some regions.
• Shift in clinical guidelines toward newer antihypertensive classes impacts overall volume but maintains a base demand for propranolol.

Pricing and Revenue Trends

• Similar to HCTZ, the drug's revenue relies on volume sales with minimal profit margins.
• Global sales are comparable to HCTZ, with the majority in North America and Europe.
• Price erosion occurs as generic manufacturing saturates the market.

What Are the Financial Trajectories and Trends?

Historical Revenue Patterns

• Both drugs have experienced steady, albeit declining, revenues since patent expirations in the late 2000s and early 2010s.
• The global market for antihypertensive drugs, including HCTZ and propranolol, was valued at approximately $30 billion in 2021 [1].
• The specific share attributable to these two drugs has diminished as newer agents capture market share.

Current Revenue Estimates

Drug	Estimated 2022 Global Revenue	Key Market Regions	Patent Status
Hydrochlorothiazide	~$200 million	North America, Europe	Generic; expired patents, widespread competition
Propranolol Hydrochloride	~$150 million	North America, Europe	Generic; expired patents, stable demand

Future Outlook

• Revenue is expected to decline incrementally over the next five years as differential use patterns favor newer agents.
• Limited pipeline activity exists for reformulations or new indications, constraining growth prospects.

Competitive Landscape

• Presence of multiple generic manufacturers reduces prices and margins.
• Patent cliffs have saturated the market, maintaining low prices and minimal innovation.
• Regulatory shifts towards safety monitoring can influence future demand, especially for HCTZ.

How Do Regulatory and Market Policies Affect These Drugs?

• Regulatory agencies like the FDA and EMA have issued safety communications impacting prescribing behaviors—especially regarding HCTZ’s long-term safety profile.
• Global shifts toward generic prescribing lower healthcare costs but also diminish profitability for producers.
• Use of these drugs in off-label contexts drives some demand, although less predictable.

Key Takeaways

• Both hydrochlorothiazide and propranolol hydrochloride operate in highly saturated markets facilitated by long patent expirations.
• Market revenue is steadily declining but remains substantial due to high-volume use and essential roles in cardiovascular management.
• Safety updates and clinical guideline shifts influence prescribing patterns, further constraining growth.
• Competitive pressure from newer drugs and generics keeps prices low, limiting profit margins for manufacturers.
• Limited innovation in reformulation or expansion hampers new revenue growth avenues.

FAQs

1. What factors could reverse the declining trend for these drugs?
Introduction of new formulations, expanded indications, or significant safety improvements could stimulate demand and revenue.

2. Are patent protections still relevant for hydrochlorothiazide and propranolol?
No, both drugs have long gone off patent, resulting in widespread generic manufacturing.

3. How does safety data impact future use?
Adverse safety data, especially for HCTZ, prompts clinicians to switch to alternative agents, reducing its market share.

4. What is the role of off-label use in market sustainability?
Off-label prescribing for conditions like anxiety with propranolol sustains some demand but remains limited in growth potential.

5. How are emerging markets influencing the global market?
Growing healthcare infrastructure in developing countries sustains demand for low-cost generics, supporting incremental revenue.

---

Sources

[1] IQVIA, "Global Use of Pharmaceutical Drugs 2022."